| Lineage |
Neuron > Hypoactive |
| Markers |
Reduced c-Fos, Decreased Arc, p-STAT3 |
| Brain Regions |
Prefrontal Cortex, Hippocampus, Basal Ganglia, Amygdala |
| Disease Relevance |
Alzheimer's Disease, Parkinson's Disease, Major Depressive Disorder, Schizophrenia |
Hypoactive Neurons plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Hypoactive neurons represent a state of reduced electrical and computational activity compared to healthy baseline firing patterns. This diminished activity can result from intrinsic neuronal dysfunction, reduced synaptic input, inhibitory network dominance, or neurodegenerative processes that impair neuronal viability [1]. Unlike hyperactive neurons which exhibit excessive firing, hypoactive neurons demonstrate decreased action potential generation, reduced synaptic responses, and impaired signal processing capabilities [2].
The significance of neuronal hypoactivity extends beyond simple reduction in firing rate. These neurons exist along a spectrum from mild activity reduction to complete functional silencing, and the underlying mechanisms determining where a neuron falls on this spectrum have profound implications for treatment strategies [3].
- Sodium channel downregulation: Reduced Nav1.6 expression decreases excitability [4]
- Potassium channel upregulation: Increased K+ conductance hyperpolarizes neurons [5]
- Calcium channel impairment: Reduced Cav1.2/1.3 decreases calcium-dependent firing [6]
- HCN channel hyperactivity: Enhanced HCN current reduces input resistance [7]
- Reduced glutamate release: Decreased presynaptic vesicle pools [8]
- AMPA receptor internalization: Loss of surface AMPARs reduces synaptic strength [9]
- NMDA receptor hypofunction: Altered subunit composition decreases currents [10]
- GABAergic enhancement: Increased inhibitory tone dampens activity [11]
- cAMP reduction: Decreased PKA activity impairs neuronal activation [12]
- mTOR hypofunction: Reduced protein synthesis affects neuronal function [13]
- ERK/MAPK deficiency: Impaired neurotrophic signaling [14]
- AMPK activation: Energy stress reduces neuronal activity [15]
- Reduced firing rate: Spontaneous discharge decreased by >50% [16]
- Increased firing threshold: More depolarized current required for spikes [17]
- Prolonged first spike latency: Delayed action potential initiation [18]
- Diminished burst firing: Loss of physiologically relevant bursting [19]
- Smaller EPSPs/EPSCs: Reduced amplitude of excitatory responses [20]
- Lower synaptic noise: Decreased spontaneous synaptic activity [21]
- Impaired plasticity: LTP and LTD deficits [22]
- Altered short-term dynamics: Abnormal facilitation/depression [23]
- Early memory deficits: CA1 neuronal hypoactivity correlates with episodic memory impairment [24]
- Network disconnection: Reduced hippocampal-cortical communication [25]
- Metabolic deficits: Glucose hypometabolism precedes structural atrophy [26]
- Synaptic depression: Aβ reduces synaptic activity through multiple mechanisms [27]
- Calcium dysregulation: Impaired calcium signaling reduces neuronal activation [28]
- Tau-mediated dysfunction: Hyperphosphorylated tau disrupts neuronal signaling [29]
- Cholinergic enhancement: Acetylcholinesterase inhibitors boost residual activity [30]
- NMDA receptor modulation: Memantine normalizes glutamatergic signaling [31]
- Network activation: Cognitive stimulation therapy engages hypoactive circuits [32]
- Substantia nigra degeneration: Loss of dopaminergic neurons reduces striatal activation [33]
- Basal ganglia dysfunction: Abnormal firing patterns in PD circuits [34]
- Motor cortex hypoactivity: Reduced cortical activation during movement [35]
- Pulsatile dopaminergic stimulation: Non-physiological activation patterns [36]
- D2 receptor desensitization: Altered inhibitory signaling [37]
- Indirect pathway hyperactivity: Enhanced indirect pathway activity [38]
- Dorsolateral PFC hypoactivity: Reduced metabolic activity in depression [39]
- Alpha wave dominance: Increased alpha power indicates reduced engagement [40]
- Cognitive dysfunction: Working memory and executive deficits [41]
- Glucocorticoid toxicity: Chronic stress reduces neuronal viability [42]
- BDNF reduction: Decreased neurotrophic support [43]
- Cytokine effects: Inflammation-associated neuronal suppression [44]
- Antidepressant mechanisms: SSRIs enhance neuronal activity over weeks [45]
- Ketamine effects: Rapid NMDA antagonism increases synaptic activity [46]
- Electroconvulsive therapy: Seizure-induced neuronal activation [47]
- P300 deficit: Reduced event-related potential indicates impaired processing [48]
- Gamma oscillation deficits: Impaired 40 Hz synchronization [49]
- Working memory dysfunction: DLPFC activity reduction [50]
- NMDA receptor hypofunction: Reduced glutamatergic signaling [51]
- Dopaminergic dysregulation: Complex D1/D2 interactions [52]
- GABAergic deficits: Parvalbumin interneuron dysfunction [53]
- Psychostimulants: Amphetamines increase neuronal activity [54]
- Cholinergic agents: Donepezil enhances cortical activity [55]
- Dopaminergic modulators: Bromocriptine improves prefrontal function [56]
- Transcranial magnetic stimulation: Direct cortical activation [57]
- Cognitive training: Exercise improves neuronal function [58]
- Deep brain stimulation: Motor and mood circuit modulation [59]
- Oxygen-glucose deprivation: Induces hypoactivity in neuronal cultures [60]
- Potassium channel agonists: Enhance K+ currents [61]
- Neuronal aging models: Senescent neurons show reduced activity [62]
- Reserpine treatment: Depletes monoamines [63]
- MPTP model: Dopaminergic hypoactivity in primates [64]
- Chronic stress models: Depression-like hypoactivity [65]
Hypoactive Neurons plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Hypoactive Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Steriade, M. (2000). Corticothalamic resonance, states of vigilance and behaviour. Progress in Neurobiology
- Buzsaki, G. et al. (2002). The neuron: network, cell, and circuit. In The Synaptic Organization of the Brain
- Metherate, R. (2004). Nicotinic acetylcholine receptors in sensory cortex. Learning & Memory
- Raman, I.M. & Bean, B.P. (1997). Resurgent sodium current and action potential formation in dissociated cerebellar Purkinje neurons. Journal of Neuroscience
- Standaert, D.G. et al. (1994). Molecular alterations in striatal projection neurons in Huntington's disease. Current Opinion in Neurobiology
- Moosmang, S. et al. (2005). Role of hippocampal Cav1.2 Ca2+ channels in NMDA receptor-independent synaptic plasticity. Nature Neuroscience
- Santoro, B. & Tibbs, G.R. (1999). The HCN gene family: molecular basis of the hyperpolarization-activated pacemaker channels. Annals of the New York Academy of Sciences
- Giuffrida, R. et al. (2005). Glutamate release from platelets. Journal of Neuroscience Research
- Malinow, R. & Malenka, R.C. (2002). AMPA receptor trafficking and synaptic plasticity. Annual Review of Neuroscience
- Snyder, E.M. et al. (2001). Regulation of NMDA receptor trafficking by amyloid-beta. Nature Neuroscience
- Mody, I. & Pearce, R.A. (2004). Diversity of inhibitory neurotransmission through GABA(A) and GABA(B) receptors. The Neuroscientist
- Greengard, P. (2001). The neurobiology of slow synaptic transmission. Science
- Swiech, L. et al. (2011). TOR signaling in neurons: implications for development and developmental disorders. Developmental Biology
- Thomas, G.M. & Huganir, R.L. (2004). MAPK cascade signalling and synaptic plasticity. Nature Reviews Neuroscience
- Hardie, D.G. (2007). AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nature Reviews Molecular Cell Biology
- Connors, B.W. & Gutnick, M.J. (1990). Intrinsic firing patterns of diverse neocortical neurons. Trends in Neurosciences
- Azouz, R. & Gray, C.M. (2000). Dynamic spike threshold reveals a mechanism for synaptic coincidence in cortical neurons in vivo. Proceedings of the National Academy of Sciences
- Pike, F.G. et al. (2000). Distinct frequency preferences of different types of rat hippocampal neurones in response to oscillatory input. Journal of Physiology
- Kepecs, A. & Lisman, J. (2003). How encoded neuron firing in the nucleus tractus solitarius affects the blood pressure and heart rate in rats. Progress in Biophysics and Molecular Biology
- Hessler, N.A. et al. (1993). The probability of transmitter release at a mammalian central synapse. Nature
- Crawford, D.C. & Kavalali, E.T. (2015). Molecular regulation of synaptic vesicle cycling. Annual Review of Neuroscience
- Malenka, R.C. & Bear, M.F. (2004). LTP and LTD: an embarrassment of riches. Neuron
- Zucker, R. & Regehr, W.G. (2002). Short-term synaptic plasticity. Annual Review of Physiology
- Dickerson, B.C. & Eichenbaum, H. (2010). The episodic memory system: neurocognitive development and disorders. Nature Reviews Neuroscience
- Greicius, M.D. et al. (2004). Default-mode network activity distinguishes Alzheimer's disease from healthy aging. Neurobiology of Aging
- Mosconi, L. (2005). Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging
- Walsh, D.M. et al. (2002). Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature
- Mattson, M.P. (2007). Calcium and neurodegeneration. Aging Cell
- Ballatore, C. et al. (2007). Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nature Reviews Neuroscience
- Birks, J. (2006). Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database of Systematic Reviews
- Lipton, S.A. (2007). Pathologically-activated therapeutics for neuroprotection. Nature Reviews Drug Discovery
- Woods, B. et al. (2009). Cognitive stimulation therapy for dementia. Aging & Mental Health
- Kalia, L.V. & Lang, A.E. (2015). Parkinson's disease. Lancet
- DeLong, M.R. (1990). Primate models of movement disorders of basal ganglia origin. Trends in Neurosciences
- Rascol, O. et al. (2000). Cortical motor organisation in patients with Parkinson's disease. Journal of Neurology, Neurosurgery & Psychiatry
- Nutt, J.G. et al. (2000). Long-term continuum of levodopa-induced dyskinesias. Movement Disorders
- Ahlskog, J.E. (2007). Beating a dead horse: do dopamine agonists work in advanced Parkinson's disease? Nature Reviews Neurology
- Obeso, J.A. et al. (2000). Pathophysiology of levodopa-induced dyskinesias. Movement Disorders
- Mayberg, H.S. (1997). Limbic-cortical dysregulation: a proposed model of depression. Journal of Neuropsychiatry and Clinical Neurosciences
- Niedermeyer, E. (1997). Alpha rhythms as physiological and abnormal phenomena. International Journal of Psychophysiology
- Harvey, P.O. et al. (2005). Working memory and schizophrenia. Cognitive Neuropsychiatry
- McEwen, B.S. (2000). The neurobiology of stress: from serendipity to clinical relevance. Brain Research
- Duman, R.S. & Monteggia, L.M. (2006). A neurotrophic model for stress-related mood disorders. Biological Psychiatry
- Dantzer, R. et al. (2008). From inflammation to sickness and depression. Biological Psychiatry
- Hyman, S.E. (2006). Neurotransmitters. Current Biology
- Zanos, P. & Gould, T.D. (2018). Mechanisms of ketamine action as an antidepressant. Molecular Psychiatry
- Sackeim, H.A. (1994). The cognitive effects of electroconvulsive therapy. Annals of the New York Academy of Sciences
- Pfefferbaum, A. et al. (1989). P300 in schizophrenia. Schizophrenia Research
- Spencer, K.M. et al. (2003). Abnormal neural synchrony in schizophrenia. Nature Neuroscience
- Weinberger, D.R. et al. (2001). Prefrontal neurons and the genetics of schizophrenia. Biological Psychiatry
- Coyle, J.T. & Tsai, G. (2004). NMDA receptor function, neuroplasticity, and the pathophysiology of schizophrenia. American Journal of Psychiatry
- Carlsson, A. et al. (2001). Interactions between monoamines, glutamate, and GABA in schizophrenia. Schizophrenia Bulletin
- Lewis, D.A. & Gonzalez-Burgos, G. (2008). Neuroplasticity of neocortical circuits in schizophrenia. Neuropsychopharmacology
- Spencer, R.C. et al. (2013). Psychostimulants and cognition. Journal of Neuroscience
- Birks, J.S. & Harvey, R. (2018). Donepezil for dementia due to Alzheimer's disease. Cochrane Database of Systematic Reviews
- Goldberg, T.E. & Weinberger, D.R. (2004). The effects of bromocriptine on human cognition. Journal of Neural Transmission Supplementum
- Hallett, M. (2000). Transcranial magnetic stimulation and the human brain. Nature
- Colcombe, S. & Kramer, A.F. (2003). Fitness effects on the cognitive function of older adults. Psychological Science in the Public Interest
- Kumar, R. et al. (2000). Deep brain stimulation for Parkinson's disease. Stereotactic and Functional Neurosurgery
- Goldberg, M.P. & Choi, D.W. (1993). Combined oxygen and glucose deprivation in cortical cell culture. Journal of Neuroscience
- Yuan, L.L. & Adams, J.P. (2007). Regulation of neuronal ion channels by voltage-gated potassium channels. Current Drug Targets
- Burke, S.N. & Barnes, C.A. (2006). Neural plasticity in the ageing brain. Nature Reviews Neuroscience
- Pletscher, A. (1991). The discovery of reserpine and its modern use. Annals of the New York Academy of Sciences
- Jenner, P. (2003). The MPTP-treated primate as a model of motor complications in Parkinson's disease. Neurology
- Katz, R.J. (1982). Animal model of depression: pharmacological sensitivity of a hedonic deficit. Pharmacology Biochemistry and Behavior